ASCO GI 2024 | NABNEC: nab-paclitaxel + carboplatin as 1L treatment of gastrointestinal neuroendocrine carcinomas

Lorraine A. Chantrill, PhD, Wollongong Hospital, New South Wales, Australia, presents findings from the NABNEC (ACTRN12616000958482) study, a non-comparative Phase II trial exploring the efficacy of carboplatin and nab-paclitaxel in advanced G3 gastrointestinal neuroendocrine neoplasms (GI-NENs). With 58 evaluable patients, the experimental arm demonstrated a 53% objective response rate (RR), surpassing the control group’s 42%. Although progression-free survival (PFS) showed no significant difference, the 24-month overall survival was 25% in the experimental group and 17% in the control. Grade 3 toxicity was higher with nab-paclitaxel. The study supports the combination’s activity in G3 GI-NENs, warranting further evaluation in a Phase III trial. This interview took place at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.